Association of IL-10 gene rs1554286 (G/A) polymorphism with prognosis of patients with primary hepatocellular carcinoma

doi:10.3877/cma.j.issn.1674-0785.2023.11.006

Abstract

Abstract:

Objective

To explore the association between the interleukin-10 (IL-10) gene single nucleotide polymorphism (SNP) rs1554286 (G/A) and the prognosis of patients with primary hepatic carcinoma (PHC) in Yanbian area, in order to provide theoretical basis for finding biomarkers that can predict the prognosis of PHC patients.

Methods

From November 2003 to November 2015, a total of 191 patients with PHC were selected from Yanbian Tumor Hospital and Yanbian University Affiliated Hospital. DNA in blood samples was extracted using a whole blood DNA extraction kit. Polymerase chain reaction (PCR) primers were designed to amplify the DNA sequence containing the SNP site. Massarray SNP genotyping technology was used to analyze the genotype of the SNP site.

Results

The IL-10 gene locus rs1554286 has G and A alleles and AA, GG, and GA genotypes. The genotype distribution frequency in the 191 patients with PHC was consistent with the law of Hardy-Weinberg equilibrium (P>0.05). There are 154 cases in the death group and 37 cases in the surviving group. There was a statistically significant difference in history of hepatitis and undergoing surgery or not between the two groups (P<0.05), but there was no significant difference in age, sex, ethnicity, drinking, smoking, or tumor stage between them (P>0.05). PHC patients with a history of hepatitis, surgery, and low tumor stage had a longer median survival time (P<0.05). The dominant model showed that the median survival time of PHC patients with rs1554286 AA genotype was longer than that of patients with GG+GA genotype (P<0.05).

Conclusion

The IL-10 SNP rs1554286 (G/A) is associated with the prognosis of PHC patients. Having the rs1554286 A allele is a protective factor for the prognosis of PHC patients.

Key words: Primary hepatic carcinoma, Single nucleotide polymorphism, Median survival time

Xiyang Xiao, Guang Jin, Runjie Sun, Hesong Cui. Association of IL-10 gene rs1554286 (G/A) polymorphism with prognosis of patients with primary hepatocellular carcinoma[J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(11): 1169-1175.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2023.11.006

https://zhlcyszz.cma-cmc.com.cn/EN/Y2023/V17/I11/1169

Figures/Tables 15

References 18

1	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: Globocan Estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2021, 71(3): 209-249.
2	蒋刈, 戴朴, 韩东一. 单核苷酸多态性在人类基因组学发展中的应用 [J]. 中华耳科学杂志, 2017, 15(2): 239-244.
3	Kuang X J, Mo D C, Qin Y, et al. Single nucleotide polymorphism of rs2596542 and the risk of hepatocellular carcinoma development: A meta-analysis [J]. Medicine (Baltimore), 2019, 98(11): e14767.
4	Li M, Yue C, Zuo X, et al. The effect of interleukin 10 polymorphisms on breast cancer susceptibility in Han women in Shaanxi Province [J]. PLoS One, 2020, 15(5): e0232174.
5	Fan P, Zhang Z, Lu L, et al. Association of single nucleotide polymorphisms (SNPs) with gastric cancer susceptibility and prognosis in population in Wuwei, Gansu, China [J]. World J Surg Oncol, 2022, 20(1): 194.
6	Rosell R, Wei J. Single nucleotide polymorphisms (SNPs) in non-small cell lung cancer (NSCLC) patients[J]. Oncologist, 2012, 17(12): 1484-1485.
7	Asadullah K, Sterry W, Volk HD. Interleukin-10 therapy--review of a new approach [J]. Pharmacol Rev, 2003, 55(2): 241-269.
8	McKay K, Moore P C, Smoller B R, et al. Association between natural killer cells and regression in melanocytic lesions[J]. Human Pathology, 2011,42(12):1960-1964.
9	Wang Y, Hu P. Association between the Interleukin-10 -1082 G/A polymorphism and risk of hepatocellular carcinoma [J]. Afr Health Sci, 2020, 20(1): 351-358.
10	Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones [J]. J Exp Med, 1989, 170(6): 2081-2095.
11	Mannino MH, Zhu Z, Xiao H, et al. The paradoxical role of IL-10 in immunity and cancer [J]. Cancer Lett, 2015, 367(2): 103-107.
12	Ding Q, Shi Y, Fan B, et al. The interleukin-10 promoter polymorphism rs1800872 (-592C＞A), contributes to cancer susceptibility: meta-analysis of 16,785 cases and 19,713 controls [J]. PLoS One, 2013, 8(2): e57246.
13	Dai ZJ, Wang XJ, Zhao Y, et al. Effects of interleukin-10 polymorphisms (rs1800896, rs1800871, and rs1800872) on breast cancer risk: evidence from an updated meta-analysis [J]. Genet Test Mol Biomarkers, 2014, 18(6): 439-445.
14	Ding Q, Shi Y, Fan B, et al. The interleukin-10 promoter polymorphism rs1800872 (-592C＞A), contributes to cancer susceptibility: meta-analysis of 16,785 cases and 19,713 controls [J]. PLoS One, 2013, 8(2): e57246.
15	Sghaier I, Mouelhi L, Rabia NA, et al. Genetic variants in IL-6 and IL-10 genes and susceptibility to hepatocellular carcinoma in HCV infected patients [J]. Cytokine, 2017, 89: 62-67.
16	Barooah P, Saikia S, Kalita MJ, et al. IL-10 polymorphisms and haplotypes predict susceptibility to hepatocellular carcinoma occurrence in patients with hepatitis C virus infection from northeast India [J]. Viral Immunol, 2020, 33(6): 457-467.
17	Lu Z, Liu R, Wang Y, et al. Ten-eleven translocation-2 inactivation restrains IL-10-producing regulatory B cells to enable antitumor immunity in hepatocellular carcinoma [J]. Hepatology, 2023, 77(3): 745-759.
18	Sun X, Yan X, Shao R, et al. Efficacy of antiviral therapy in patients with hepatitis B-related primary liver cancer [J]. J BUON, 2021, 26(3): 897-903.

组别	生存组（n=37）	死亡组（n=154）	t/χ²	P值
性别[例（%）]			χ²=0.082	0.775
男	28（14.7%）	113（59.2%）
女	9（4.7%）	41（21.5%）
年龄（岁）	62.46±9.371	60.97±10.381	t=-0.799	0.425

组别	生存组（n=37）	死亡组（n=154）	t/χ²	P值
性别[例（%）]			χ²=0.082	0.775
男	28（14.7%）	113（59.2%）
女	9（4.7%）	41（21.5%）
年龄（岁）	62.46±9.371	60.97±10.381	t=-0.799	0.425

因素	β值	SE	Wald χ²值	P值	HR	95%CI值
年龄（≥60岁/<60岁）	-0.320	0.167	3.649	0.056	0.726	(0.523-1.008)
性别（女/男）	0.017	0.183	0.009	0.924	1.017	(0.711-1.456)
民族（汉/朝）	0.110	0.168	0.432	0.511	1.116	(0.804-1.551)
饮酒（有/无）	0.008	0.169	0.002	0.964	1.008	(0.724-1.403)
吸烟（有/无）	0.203	0.166	1.502	0.220	1.225	(0.885-1.695)
肝炎（有/无）	-0.634	0.172	13.525	0.000	0.530	(0.378-0.744)
手术^a（有/无）	-0.435	0.180	5.856	0.016	0.647	(0.455-0.921)

因素	β值	SE	Wald χ²值	P值	HR	95%CI值
年龄（≥60岁/<60岁）	-0.320	0.167	3.649	0.056	0.726	(0.523-1.008)
性别（女/男）	0.017	0.183	0.009	0.924	1.017	(0.711-1.456)
民族（汉/朝）	0.110	0.168	0.432	0.511	1.116	(0.804-1.551)
饮酒（有/无）	0.008	0.169	0.002	0.964	1.008	(0.724-1.403)
吸烟（有/无）	0.203	0.166	1.502	0.220	1.225	(0.885-1.695)
肝炎（有/无）	-0.634	0.172	13.525	0.000	0.530	(0.378-0.744)
手术^a（有/无）	-0.435	0.180	5.856	0.016	0.647	(0.455-0.921)

肝癌分期	β值	SE	Wald χ²	P值	HR	95%CI
II期/I期	0.063	0.548	0.013	0.908	1.065	（0.364~3.117）
III期/I期	0.216	0.514	0.177	0.674	1.242	（0.453~3.401）
IV期/I期	0.653	0.521	1.574	0.210	1.922	（0.693~0.533）

Please choose a citation manager

Content to export